-- American Spinal Injury Association (ASIA), June 2007;
-- World Spine, July 2007;
-- Congress of Neurological Surgeons, September 2007; and
-- North American Spine Society, October 2007
Advanced the Molecular Imaging Program.
-- In July 2007, Alseres completed a study with our collaborators that
optimized ALTROPANE's image acquisition protocol. We believe the
optimized protocol will enhance ALTROPANE's use once commercialized.
-- After a series of discussions with the FDA and our expert advisors, our
POET-2 program was designed as a two-part Phase III program using the
optimized ALTROPANE image acquisition protocol. The first part of the
program was initiated in December 2007 in a multi-center clinical study
in subjects to acquire a set of ALTROPANE images to train the expert
readers. The second part involves two concurrent, replicate, multi
center Phase III trials. These two concurrent trials will be initiated
once final agreement on the design of the two trials is reached with
-- Data from a study to evaluate the Test/Re-test reliability of ALTROPANE
in Parkinson disease patients were presented at Movement Disorder
Society's 11th International Congress of Parkinson's Disease and
Movement Disorders in June 2007. The data demonstrated that ALTROPANE
uptake is reduced in Parkinson's Disease patients with moderate PD and
has excellent test/re-test reliability.
-- We advanced partnering discussions for our Molecular Imaging Program
the focus of which was the completion of the Phase III clinical
program, development of the product in Dementia with Lewy Bodies,
development of the product in Europe, ultimately the launch and
commercialization of ALTROPANE and product family life cycle managemen
|SOURCE Alseres Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved